envudeucitinib
Generic: envu·Code: ESK-001
envudeucitinib: developed by 1 company · 1 clinical trial tracked. Updated within the last hour.
Development Pipeline (1)
| Company | Phase |
|---|---|
| ALUMIS INC. (ALMS) | Phase 3 |
Clinical Trials (1)
A Phase 2, Multicenter, Multinational, Randomized, Double-blind, Placebo-Controlled Study to Assess the Safety, Efficacy, and Pharmacokinetics of Multiple Dose Levels of ESK-001 in Adult Patients With Systemic Lupus Erythematosus
Frequently asked questions
Who is developing envudeucitinib?
envudeucitinib is being developed by ALUMIS INC..
How many clinical trials involve envudeucitinib?
BioSniper tracks 1 clinical trial involving envudeucitinib.
Get deeper analysis on envudeucitinib
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
Start Free Analysis